Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Rating Increased to Strong-Buy at Zacks Research

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Finally, Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Three analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

BAYRY opened at $12.68 on Tuesday. The firm has a market capitalization of $49.16 billion, a PE ratio of -140.87, a price-to-earnings-growth ratio of 4.74 and a beta of 0.66. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71. The business’s 50-day moving average is $10.27 and its two-hundred day moving average is $8.80. Bayer Aktiengesellschaft has a 1 year low of $5.30 and a 1 year high of $13.00.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.